Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2020 Jan 23

PMID 31965356

Citations 6

Authors

Kannika Story

Ryan Sobel

Affiliations

Soon will be listed here.

Abstract

Due to broad spectrum susceptibility of Candida species to fluconazole, its convenience as an oral agent, and predictable patient tolerance and safety, current practice guidelines recommend the use of long-term suppression regimens of fluconazole as prophylaxis for recurrent vulvovaginal candidiasis (RVVC), as well as in abbreviated doses when known trigger factors emerge and inevitable symptomatic episodes are predictable. However, recent concerns of fluconazole-resistant Candida albicans strains may impact fluconazole use, particularly, concerns of overuse. This literature review discusses current recommendations for prophylaxis of vulvovaginal candidiasis with fluconazole.

Citing Articles

Antimicrobial and anti-biofilm properties of oleuropein against Escherichia coli and fluconazole-resistant isolates of Candida albicans and Candida glabrata.

Esfandiary M, Khosravi A, Asadi S, Nikaein D, Hassan J, Sharifzadeh A BMC Microbiol. 2024; 24(1):154.

PMID: 38704559 PMC: 11069153. DOI: 10.1186/s12866-024-03305-5.

Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials.

He R, Lin F, Yu B, Huang L Heliyon. 2024; 10(8):e28776.

PMID: 38628772 PMC: 11019174. DOI: 10.1016/j.heliyon.2024.e28776.

Lived experience of medical management in recurrent vulvovaginal candidiasis: a qualitative study of an uncertain journey.

Bradfield Strydom M, Walpola R, McMillan S, Khan S, Ware R, Tiralongo E BMC Womens Health. 2022; 22(1):384.

PMID: 36123738 PMC: 9487134. DOI: 10.1186/s12905-022-01973-x.

New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets.

Brankiewicz W, Okonska J, Serbakowska K, Lica J, Drab M, Ptaszynska N Pharmaceutics. 2022; 14(4).

PMID: 35456526 PMC: 9026428. DOI: 10.3390/pharmaceutics14040693.

New Approach to Antifungal Activity of Fluconazole Incorporated into the Porous 6-Anhydro-α-l-Galacto-β-d-Galactan Structures Modified with Nanohydroxyapatite for Chronic-Wound Treatments-In Vitro Evaluation.

Rewak-Soroczynska J, Sobierajska P, Targonska S, Piecuch A, Grosman L, Rachuna J Int J Mol Sci. 2021; 22(6).

PMID: 33803717 PMC: 8003069. DOI: 10.3390/ijms22063112.

References

Marchaim D, Lemanek L, Bheemreddy S, Kaye K, Sobel J . Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012; 120(6):1407-14. DOI: 10.1097/aog.0b013e31827307b2. View

Berard A, Sheehy O, Zhao J, Gorgui J, Bernatsky S, de Moura C . Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019; 191(7):E179-E187. PMC: 6379167. DOI: 10.1503/cmaj.180963. View

Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R . Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008; 199(6):613.e1-9. DOI: 10.1016/j.ajog.2008.06.029. View

Bitew A, Abebaw Y . Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018; 18(1):94. PMC: 6003188. DOI: 10.1186/s12905-018-0607-z. View

Maraki S, Mavromanolaki V, Stafylaki D, Nioti E, Hamilos G, Kasimati A . Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. Mycoses. 2019; 62(8):692-697. DOI: 10.1111/myc.12946. View

Sobel J, Chaim W, Nagappan V, Leaman D . Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003; 189(5):1297-300. DOI: 10.1067/s0002-9378(03)00726-9. View

Yano J, Sobel J, Nyirjesy P, Sobel R, Williams V, Yu Q . Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019; 19(1):48. PMC: 6441174. DOI: 10.1186/s12905-019-0748-8. View

Sobel J, Faro S, FORCE R, Foxman B, Ledger W, Nyirjesy P . Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998; 178(2):203-11. DOI: 10.1016/s0002-9378(98)80001-x. View

Yan L, Wang X, Seyedmousavi S, Yuan J, Abulize P, Pan W . Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. Mycopathologia. 2019; 184(3):413-422. DOI: 10.1007/s11046-018-0305-2. View

10.

Workowski K, Bolan G . Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03):1-137. PMC: 5885289. View

11.

Sobel J, Ohmit S, Schuman P, Klein R, Mayer K, Duerr A . The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2001; 183(2):286-93. DOI: 10.1086/317936. View

12.

Sobel J, Wiesenfeld H, Martens M, Danna P, Hooton T, Rompalo A . Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004; 351(9):876-83. DOI: 10.1056/NEJMoa033114. View